Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

PURPOSE: In KATHERINE, adjuvant T-DM1 reduced risk of disease recurrence or death by 50% compared with trastuzumab in patients with residual invasive breast cancer after neoadjuvant therapy (NAT) comprised of HER2-targeted therapy and chemotherapy. This analysis aimed to identify biomarkers of respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Denkert, Carsten, Lambertini, Chiara, Fasching, Peter A., Pogue-Geile, Katherine L., Mano, Max S., Untch, Michael, Wolmark, Norman, Huang, Chiun-Sheng, Loibl, Sibylle, Mamounas, Eleftherios P., Geyer, Charles E., Lucas, Peter C., Boulet, Thomas, Song, Chunyan, Lewis, Gail D., Nowicka, Malgorzata, de Haas, Sanne, Basik, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102844/
https://www.ncbi.nlm.nih.gov/pubmed/36730339
http://dx.doi.org/10.1158/1078-0432.CCR-22-1989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102844/
https://www.ncbi.nlm.nih.gov/pubmed/36730339
http://dx.doi.org/10.1158/1078-0432.CCR-22-1989

Ejemplares similares